BeijingJune 17, 2026 /PRNewswire/ — On June 12, 2026, the Oligonucleotide Drug Salon (Shanghai), hosted by Qingke Biotech, was successfully held at the Shanghai Zhangjiang Hilton Hotel. The salon focused on core topics such as sequence design and delivery innovation, CMC development, and IND filing, bringing together numerous industry experts from research institutions, biomedical companies, and investment organizations to discuss the development opportunities and key challenges in the field of small nucleic acid drugs.
As small nucleic acid drugs gradually enter an accelerated industrialization phase, this event was not only a technical exchange but also a deep dialogue about the future of the industry.
Industry Enters an Acceleration Phase: Exchange Matters More Than Answers
At the beginning of the meeting, Mr. Ma Shijin, Chairman and President of Qingke Biotech, delivered an opening speech. Mr. Ma stated that China’s small nucleic acid industry is at a critical stage of transitioning from “following” to “running alongside,” and even “leading” in some areas. Everyone present is both a witness and a driver of industrial development. At the same time, he shared Qingke’s original intention in hosting this salon: to build an open, practical, and pure communication platform where real industry issues can be confronted and deep insights can collide. The development of small nucleic acid drugs relies on collaborative innovation across the entire industry chain, from upstream synthesis, delivery technology, and CMC processes to policy regulation, all requiring joint exploration and promotion by all parties.
Technical Depth: Deep Dialogue from Sequence Design to IND
Dr. Bai Jun, Head of the Nucleic Acid Research Department at Haichang Biotech, systematically outlined the development trajectory of siRNA drugs from sequence design and chemical modification to delivery platforms, with a focus on the latest advances in frontier directions such as GalNAc, AOC, dual-target small nucleic acids, adipose tissue targeting, and kidney delivery. From technological evolution to future trends, the presentation comprehensively showcased the innovative vitality in the field of small nucleic acid drug development and provided attendees with rich research inspiration.
Professor Chen Qixian, a professor at the Zhejiang University Yangtze River Delta Smart Green Innovation Center and Chief Scientist at Qingke Biotech, started from the fundamental scientific question of “how rigid dsDNA condenses” and shared his team’s series of research findings in the field of nucleic acid delivery. The presentation highlighted achievements such as lysosomal bypass through fluorination modification, non-liver targeting delivery breakthroughs using multi-target nanomicelles, and exploratory practices in central nervous system and tumor delivery, offering new research ideas for the long-standing industry challenge of non-liver targeting delivery.
Dr. Wang Yaning, Founder and CEO of Ruiningkang Biotech, former Head of the FDA’s Office of Clinical Pharmacology, and Chief Scientific Advisor at Qingke Biotech, provided an in-depth analysis of several representative FDA approval cases from a firsthand perspective. Focusing on scientific evidence, surrogate endpoint selection, and regulatory decision-making logic, Dr. Wang shared his extensive review experience and, combined with the current state of industry development, offered a thorough interpretation of key issues in the clinical development and registration filing of small nucleic acid drugs. These insights are of significant reference value for companies currently advancing IND filings and clinical development.
Dr. Zhao Chengjiang, Co-founder of Youjia Biotech, systematically deconstructed the key CMC decision points involved in the process from sequence determination to IND filing for small nucleic acid drugs, drawing on years of project practice experience. Focusing on core aspects such as synthesis processes, analytical methods, formulation delivery, quality standards, and toxicology batch production, Dr. Zhao shared experiences and reflections from project advancement and elaborated on the critical value of the CMC system for drug development from an industrialization perspective. Every technical choice made during the R&D phase will be continuously validated and amplified in subsequent development, and a robust CMC system is a crucial foundation for facilitating the smooth translation of projects.
Dr. Chen Xizhao, Head of Small Nucleic Acid Technology at Qingke Biotech, presented on the “Full-Process Development Platform for Oligonucleotide Drugs: From Hit Screening to CMC Industrialization Practice,” systematically introducing Qingke’s capability layout in the field of small nucleic acid drug R&D and industrialization services. The presentation showcased an integrated service system covering sequence design, modification optimization, process development, and CMC research, providing innovative drug companies with new collaborative ideas to accelerate project progress.
Clash of Perspectives: Opportunities and Challenges in the Industrialization Process
The roundtable forum was moderated by Du Jun, Vice President of Qingke Biotech, with participation from Dr. Wang Yaning, Dr. Zhao Chengjiang, Professor Chen Qixian, and Zhao Xiaozan, Investment Director of Shanghai Sinan Park Investment. The guests engaged in in-depth discussions on hot topics in the R&D and industrialization of small nucleic acid drugs, sharing industry observations and practical experiences from multiple dimensions, including technological innovation, CMC development, regulatory review, and capital perspectives.
Different perspectives from various fields and roles collided on site, prompting attendees to think more deeply about the future development direction of small nucleic acid drugs. Industrial development is never a single-point breakthrough but the result of collaborative progress among technology, regulation, capital, and the industry chain.
Rooted in Core Nucleic Acid Capabilities, Serving the Full Lifecycle of Small Nucleic Acid Drugs
As the host of this salon, Qingke Biotech has always been deeply rooted in the nucleic acid field, continuously advancing the construction of technology and service platforms related to small nucleic acid drugs.
Leveraging its self-developed nucleic acid synthesis equipment, core raw material systems, and large-scale production platform, Qingke has built a full-process service capability covering R&D-grade to GMP-grade, providing customers with one-stop support from sequence design to industrialized production. Currently, Qingke has established a service system covering the entire R&D cycle of small nucleic acid drugs:
Nucleic Acid Synthesis and Modification Platform
Supports custom development of siRNA, ASO, and various modified oligonucleotides, covering mainstream modification types such as 2′-OMe, 2′-F, PS, and GalNAc conjugation, meeting the needs of different R&D stages.
Small Nucleic Acid Drug CDMO Platform
Covers full-chain services from Hit screening, Lead optimization, process development, analytical testing, to IND-Enabling studies, providing customers with efficient and stable integrated CMC solutions.
Analytical Testing Platform
Establishes a comprehensive oligonucleotide analytical method system to meet the quality research and data support needs during R&D and IND filing stages.
As one of the early companies in China to lay out the nucleic acid industry chain, Qingke not only specializes in nucleic acid synthesis services but also continuously drives underlying technological innovation and industrial capability building.
From self-developed nucleic acid synthesis equipment to core raw material development, innovative modification technology, and large-scale GMP production platform construction, Qingke has gradually built an independent technology system covering the entire industry chain.
At the same time, leveraging years of accumulated experimental data and technical experience, Qingke is actively deploying an AI-assisted drug development platform, continuously exploring the application of AI technology in nucleic acid sequence design, candidate molecule screening, and process optimization, providing customers with more efficient and intelligent R&D support.
In the industrialization phase, Qingke is also continuously strengthening its small nucleic acid CDMO capabilities, meeting customers’ growing needs from R&D to commercialization through large-scale production platforms and mature process systems.
Small Nucleic Acids, Big Era
Currently, the small nucleic acid drug industry is facing unprecedented development opportunities.
From technological innovation to clinical translation, from laboratory research to industrial implementation, every breakthrough relies on collaborative innovation and joint efforts across the industry chain.
From laboratory innovation to clinical translation, from technological breakthroughs to industrial landing, China’s small nucleic acid industry is ushering in its own golden period of development.
In the future, Qingke Biotech will continue to collaborate with research institutions, innovative drug companies, and industry partners to jointly promote technological progress and industrial development in the field of small nucleic acid drugs, providing solid support for more innovative therapies to reach clinical practice and the market.
The explosion of the small nucleic acid track is not a future scenario but a reality unfolding now.
Qingke Biotech looks forward to walking alongside you.